MedPath

AMGEN TO PRESENT DATA FROM MULTIPLE EARLY-STAGE CLINICAL TRIALS AT ESMO 2024

Amgen presents new oncology data at ESMO Congress 2024, highlighting targeted therapies for colorectal, lung, prostate, and gastric cancers, reflecting its strategy to advance diverse modalities for difficult-to-treat cancers.


Reference News

AMGEN TO PRESENT DATA FROM MULTIPLE EARLY-STAGE CLINICAL TRIALS AT ESMO 2024

Amgen presents new oncology data at ESMO Congress 2024, highlighting targeted therapies for colorectal, lung, prostate, and gastric cancers, reflecting its strategy to advance diverse modalities for difficult-to-treat cancers.

AMGEN TO PRESENT DATA FROM MULTIPLE EARLY-STAGE CLINICAL TRIALS AT ESMO 2024

Amgen presents new oncology data at ESMO Congress 2024, highlighting targeted therapies for colorectal, lung, prostate, and gastric cancers, reflecting their strategy to advance diverse modalities for difficult-to-treat cancers.

AMGEN TO PRESENT DATA FROM MULTIPLE EARLY-STAGE CLINICAL TRIALS AT ESMO 2024

Amgen presents new oncology data at ESMO 2024, highlighting targeted therapies for colorectal, lung, prostate, and gastric cancers, reflecting its strategy to advance diverse modalities for difficult-to-treat cancers.

© Copyright 2025. All Rights Reserved by MedPath